Literature DB >> 2369416

Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors.

F Guillemin1, S Briançon, J Pourel, A Gaucher.   

Abstract

Prognostic factors for the occurrence of longterm disability and prolonged sick leave were determined in 182 patients with ankylosing spondylitis. A significant relationship appeared between functional disability (determined by the Stanford Health Assessment Questionnaire) and sex, age at disease onset, and the number of peripheral joints involved. Using a life-table approach, the probability of prolonged sick leaves was associated with peripheral joint involvement and work that involved carrying heavy loads. Long-term disability was more frequent after work involving exposure to cold conditions (relative risk [RR] = 2.01) and prolonged standing postures (RR = 1.34), while sedentary work (RR = 0.35) and formal vocational rehabilitation programs (RR = 0.57) seemed to protect against long-term disability.

Entities:  

Mesh:

Year:  1990        PMID: 2369416     DOI: 10.1002/art.1780330712

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

1.  Employment perspectives of patients with ankylosing spondylitis.

Authors:  A M J Chorus; A Boonen; H S Miedema; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

2.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 3.  [Ankylosing spondylitis--current state of imaging including scoring methods].

Authors:  C E Althoff; K G Hermann; J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

4.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

5.  Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis.

Authors:  Michael M Ward; John D Reveille; Thomas J Learch; John C Davis; Michael H Weisman
Journal:  Arthritis Rheum       Date:  2008-06-15

6.  Risk factors for functional limitations in patients with long-standing ankylosing spondylitis.

Authors:  Michael M Ward; Michael H Weisman; John C Davis; John D Reveille
Journal:  Arthritis Rheum       Date:  2005-10-15

7.  Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients.

Authors:  A Boonen; A Chorus; H Miedema; D van der Heijde; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

8.  Withdrawal from labour force due to work disability in patients with ankylosing spondylitis.

Authors:  A Boonen; A Chorus; H Miedema; D van der Heijde; R Landewé; H Schouten; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

9.  A multidisciplinary job retention vocational rehabilitation programme for patients with chronic rheumatic diseases: patients' and occupational physicians' satisfaction.

Authors:  P D M de Buck; J Breedveld; F J van der Giesen; T P M Vliet Vlieland
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

10.  Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs.

Authors:  Britta Strömbeck; Lennart T H Jacobsson; Ann Bremander; Martin Englund; Anders Heide; Aleksandra Turkiewicz; Ingemar F Petersson
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.